ArticleScientific reports2025
Integrated analysis of m6A regulator mediated RNA methylation and key immune related genes in ischemic stroke.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of N6-methyladenosine associated genes in ischemic stroke risk: interplay with environmental factors.Journal of thrombosis and thrombolysis · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The role of RNA N6-methyladenosine (m6A) modifications in modulating the immune microenvironment during ischemic stroke (IS) pathogenesis remains poorly characterized. This investigation systematically explores m6A-mediated immune regulation in IS and identifies critical immune-related biomarkers. Transcriptomic profiles from 108 IS samples were analyzed to discern m6A regulatory patterns. Single-sample gene set enrichment analysis (ssGSEA) and gene set variation analysis (GSVA) quantified immune cell infiltration and pathway activity across IS subtypes and controls. Weighted gene co-expression network analysis (WGCNA) identified m6A-associated gene modules. Two complementary machine learning approaches were applied to identify the key immune-related genes implicated in IS pathogenesis. The robustness of these findings was subsequently confirmed through a comprehensive meta-analysis integrating six independent datasets. Eight dysregulated m6A regulators distinguished IS from controls. Unsupervised clustering delineated two distinct m6A modification patterns (Clusters A/B) with divergent immune landscapes: Cluster B exhibited heightened infiltration of natural killer cells, eosinophils, and activated CD4 T cells, coupled with IL6/JAK/STAT3 pathway activation, whereas Cluster A demonstrated enrichment of immature dendritic cells and monocytes, alongside oxidative phosphorylation signaling. WGCNA identified a conserved immune-related module (black module, r = 0.68 with Cluster B) containing 322 co-expressed genes. Cross-validation by machine learning nominated five candidate biomarkers (ABCA1, CPD, PRRG4, WDR46, C19orf24) showing consistent expression trends in internal validation cohorts (Control vs. IS and Cluster A vs. B). External validation via meta-analysis confirmed WDR46 as a protective factor against IS susceptibility (odds ratio [OR] = 0.74, 95% confidence interval [CI]: 0.57–0.97), while CPD (OR = 1.46, 95% CI: 1.01–2.10) and ABCA1 (OR = 1.57, 95% CI: 1.12–2.22) were significantly associated with increased IS susceptibility, establishing their roles as risk genes. Subsequent RT-qPCR analysis in clinical samples further validated the results of the aforementioned external validation. Moreover, ROC analysis revealed an AUC of 0.88 (95% CI: 0.82–0.94) for ABCA1, 0.82 (95% CI: 0.74–0.89) for WDR46, and 0.90 (95% CI: 0.84–0.96) for CPD. This study establishes m6A epitranscriptomic remodeling as a pivotal orchestrator of immune microenvironment heterogeneity in IS. The identification of ABCA1, CPD, and WDR46 as promising biomarkers not only enhances the potential for precise diagnosis but also provides actionable targets for immunomodulatory therapy in IS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.